Biotech Values

[DewDiligence]

FDA approves NVS’ Afinitor for kidney tumors associated tuberous sclerosis complex:

http://finance.yahoo.com/news/novartis-drug-afinitor-approved-fda-221800566.html

This is not a major indication from a commercial standpoint, but it’s another feather in NVS’ cap for getting the first approved drug in this indication.

Afinitor has turned into an impressive drug in terms of its sales and its wide applicability.